Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2025-03-30
Target enrollment:
Participant gender:
Summary
A multi-cohort, open-label, multicenter exploratory clinical study of Bemalenograstim alfa
for the prevention of reduced absolute neutrophil count(ANC) in patients with colorectal
cancer/pancreatic cancer following a bi-weekly chemotherapy regimen.A total of 89 patients
are planned to be enrolled.
Phase:
Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University